March 17, 2022 – Medtronic plc announced new executive appointments for three of its operating units: Diabetes, Robotics, and Cardiac Rhythm Management.
Que Dallara joined the company as EVP and Operating Unit President, Diabetes, effective May 2, 2022. Dallara comes from Honeywell where she served as President and CEO of Honeywell Connected Enterprise, and earlier as SVP and chief commercial officer. She also held general manager and strategy roles at TE Connectivity Ltd. and Microsoft, after working at McKinsey in her early career.
In this role, Dallara succeeds Sean Salmon, EVP and president, Cardiovascular Portfolio and Diabetes Operating Unit, who now turns to focus exclusively on leading the Cardiovascular Portfolio. Salmon will ensure continuity and support Dallara’s transition into the Diabetes business. He continues as a member of the Medtronic Executive and Capital Allocation Committees, helping to lead the company’s enterprise strategy.
Mike Marinaro was named as President, Surgical Robotics. Marinaro has more than 20 years of experience at Medtronic. Previously, he led the Cardiac Rhythm Management Operating Unit with annualized revenue of more than $4 billion. Under Marinaro’s leadership, the business launched and scaled the Micra leadless pacemaker product line to more than $400 million annualized revenue.
Marinaro succeeds Megan Rosengarten, who is taking a planned six-month sabbatical to spend more time with her family. Rosengarten has successfully led the Surgical Robotics business for the past four years, steering the Hugo RAS System from early development to commercialization, and leading the acquisition of the Digital Surgery business.
Dr. Kweli Thompson was named as President, Cardiac Rhythm Management. Dr. Thompson is an accomplished medical technology leader with two decades of experience in business development, clinical research, product marketing, and general management. Previously, as VP and general manager of the Cardiac Resynchronization and Defibrillation Solutions businesses, a part of Cardiac Rhythm Management, he led Defibrillation Solutions to the highest market share in three years and the highest Cardiac Resynchronization Therapy market share in more than a decade.